Trial Profile
Allergen Challenge
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Anrukinzumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Pfizer
- 22 Jun 2008 Actual end date is May 2008 as reported by ClinicalTrials.gov.
- 22 Jun 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 27 Dec 2007 The expected completion date for this trial is now 1 Jun 2008.